Market Cap | 39.47M | P/E | - | EPS this Y | 123.10% | Ern Qtrly Grth | - |
Income | 608k | Forward P/E | -14.88 | EPS next Y | 33.30% | 50D Avg Chg | 9.00% |
Sales | 36.43M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 11.00% |
Dividend | N/A | Price/Book | 0.96 | EPS next 5Y | - | 52W High Chg | -66.00% |
Recommedations | 1.50 | Quick Ratio | 4.24 | Shares Outstanding | 16.68M | 52W Low Chg | 72.00% |
Insider Own | - | ROA | 0.73% | Shares Float | 22.27M | Beta | 0.32 |
Inst Own | 21.91% | ROE | 1.44% | Shares Shorted/Prior | 27.17K/37.68K | Price | 2.38 |
Gross Margin | 74.82% | Profit Margin | 1.67% | Avg. Volume | 52,890 | Target Price | 12.40 |
Oper. Margin | 5.86% | Earnings Date | Nov 13 | Volume | 3,252 | Change | 1.71% |
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
HC Wainwright & Co. | Buy | Sep 16, 24 |
HC Wainwright & Co. | Buy | Aug 8, 24 |
Northland Capital Markets | Outperform | Aug 7, 24 |
HC Wainwright & Co. | Buy | Jun 5, 24 |
Oppenheimer | Outperform | May 9, 24 |
HC Wainwright & Co. | Buy | May 9, 24 |
HC Wainwright & Co. | Buy | Mar 11, 24 |
Oppenheimer | Outperform | Nov 16, 23 |
Raymond James | Market Perform | Nov 16, 23 |